Results 41 to 50 of about 658,116 (357)

Connective tissue growth factor is a new ligand of epidermal growth factor receptor [PDF]

, 2013
Chronic kidney disease is reaching epidemic proportions worldwide and there is no effective treatment. Connective tissue growth factor (CCN2) has been suggested as a risk biomarker and a potential therapeutic target for renal diseases, but its specific ...
Abreu, Adams, Allen, Ardura, Asakura, Bradshaw, Bronte, Cabodi, Chen, Chen, De Winter, Dreux, El Zein, Flamant, Fragiadaki, Gao, Gao, Guha, Hao, Hashimoto, Humphries, Inoki, Juliano, Kim, Lam, Lautrette, Leask, Liu, Liu, Markiewicz, Melenhorst, Miranti, Moro, Ohtsu, Okada, Perbal, Phanish, Plow, Pourazar, Rachfal, Riser, Rojas, Ruiz-Ortega, Rupérez, Schwartz, Segarini, Sibilia, Slagman, Sweeney, Sánchez-López, Tam, Terzi, Wahab, Wang, Wang, Wolf, Yokoi   +56 more
core   +1 more source

Selective Desensitization of Growth Factor Signaling by Cell Adhesion to Fibronectin [PDF]

, 2007
Cell adhesion to the extracellular matrix is required to execute growth factor (GF)-mediated cell behaviors, such as proliferation. A major underlying mechanism is that cell adhesion enhances GF-mediated intracellular signals, such as extracellular ...
Asthagiri, Anand R., Galownia, Niki C., Gong, Yuan, Kushiro, Keiichiro   +3 more
core   +1 more source

NRASQ61R Expression in Lymphatic Endothelial Cells Causes Enlarged Vessels, Hemorrhagic Chylous Effusions, and High Mortality in a Mouse Model of Kaposiform Lymphangiomatosis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Kaposiform lymphangiomatosis (KLA) is an aggressive complex lymphatic anomaly. Patients exhibit malformed lymphatic vessels and often develop hemorrhagic effusions and elevated angiopoietin‐2 (Ang‐2) levels. A somatic NRAS p.Q61R (NRASQ61R) mutation has been associated with KLA.
C. Griffin McDaniel, Patricia Pastura, Joshua P. Scallan, Timothy D. Le Cras   +3 more
wiley   +1 more source

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients

Clinics, 2012
OBJECTIVE: Epidermal growth factor receptor is involved in the pathogenesis of non-small cell lung cancer and has recently emerged as an important target for molecular therapeutics.
Carlos E. Bacchi, Heloísa Ciol, Eduardo M. Queiroga, Lucimara C. Benine, Luciana H. Silva, Elida B. Ojopi   +5 more
doaj   +1 more source

Efficacy of Next-Generation EGFR-TKIs in Patients With Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Technology in Cancer Research & Treatment, 2020
Background: The efficacy of next-generation epidermal growth factor receptor-tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer who have failed first-generation epidermal growth factor receptor-tyrosine kinase inhibitors ...
Yi-Tian Qi MM, Yi Hou PhD, Liang-Chen Qi MD   +2 more
doaj   +1 more source

Activation of tyrosine kinases by mutation of the gatekeeper threonine. [PDF]

, 2008
Protein kinases targeted by small-molecule inhibitors develop resistance through mutation of the gatekeeper threonine residue of the active site. Here we show that the gatekeeper mutation in the cellular forms of c-ABL, c-SRC, platelet-derived growth ...
Azam, Mohammad, Daley, George, Gray, Nathanael, KURIYAN, John, Seeliger, Markus   +4 more
core   +1 more source

Epidermal growth factor-induced truncation of the epidermal growth factor receptor

Journal of Biological Chemistry, 1989
NIH-3T3 cells expressing the human epidermal growth factor (EGF) receptor were used in experiments to determine the fate of the EGF receptor in cells continuously exposed to EGF. EGF receptor was immunoprecipitated from cells labeled for 12 h with [35S] methionine in the absence or presence of 10 nM EGF.
openaire   +2 more sources

Health‐Related Quality of Life and Symptom Severity Among Patients With PIK3CA‐Related Overgrowth Spectrum: A Mixed‐Methods Study to Understand Real‐World Experience With Alpelisib Treatment

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background PIK3CA‐related overgrowth spectrum (PROS) includes several rare overgrowth disorders resulting from somatic gain‐of‐function mutations in PIK3CA. Despite treatment advances, including the recent approval of alpelisib for PROS in the United States, literature detailing the patient experience with PROS is limited.
Vamsi Bollu, Kaitlin LaGasse, Cory D. Saucier, Kimberly Raymond, Miranda Lauher‐Charest, Lauren Crowder, Beilei Cai, Mary Lisha Paul, Denise Adams   +8 more
wiley   +1 more source

Prevalence and clinicopathological features of human epidermal growth factor receptor-2–low breast cancers: A single-center experience

Journal of International Medical Research
Objective Human epidermal growth factor receptor-2–low breast cancer, characterized by low-level human epidermal growth factor receptor-2 expression and immunohistochemistry score 1+ or immunohistochemistry score 2+ without amplification, has been ...
ılkay Cinar
doaj   +1 more source

miRNA-9 Inhibits Proliferation and Migration of Lung Squamous Cell Carcinoma Cells by Regulating NRSF/EGFR

Technology in Cancer Research & Treatment, 2020
Background: To investigate the mechanism of microRNA9 in inhibiting proliferation and migration of lung squamous cell carcinoma cells via neuron-restricted silencing factor/epidermal growth factor receptor.
Kangning Wang MD, Kai Xu MM, Xuefeng Leng MD, Yongtao Han BM, Qiang Fang MD   +4 more
doaj   +1 more source